Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Naloxone
(D08249)
[1] Naloxone[1] Naloxone (D08249) 💬[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[2] 6, 226 💬
2NALOXONE HYDROCHLORIDE
(D08249)
[1] Naloxone[1] Naloxone (D08249) 💬[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 226 💬
3NALOXONE HYDROCHLORIDE DIHYDRATE
(D08249)
[1] Naloxone[1] Naloxone (D08249) 💬[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 6 💬
4Oxycodone naloxone prolonged release tablets
(D08249)
[2] Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 226 💬
5Oxycodone/naloxone prolonged release t
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 226 💬
6Oxycodone/Naloxone Prolonged Release tablets
(D08249)
[2] Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 6 💬
7Oxycodone/naloxone prolonged release tablets 10 mg /5 mg
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 6 💬
8Oxycodone/naloxone prolonged release tablets 10/5 mg
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 226 💬
9Oxycodone/naloxone prolonged release tablets 20 mg /10 mg
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 6 💬
10Oxycodone/naloxone prolonged release tablets 20/10 mg
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 226 💬
11Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 6 💬
12Oxycodone/naloxone prolonged release tablets 5/2.5 mg
(D08249)
[3] Manganese citrate,
Naloxone,
Oxycodone
[2] Oxycodone ,
Naloxone (D08249) 💬
[3] OPRD1,
OPRK1,
OPRM1 💬
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬[1] 226 💬